Rhythm Pharmaceuticals Announces New Employment Inducement Grants
December 07, 2022 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals to Present at BofA Securities 2022 Virtual Biotech SMID Cap Conference
December 01, 2022 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces ▼IMCIVREE® (setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
November 21, 2022 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- Health Canada accepts for review new drug submission for setmelanotide for the treatment of obesity and control of hunger in BBS and biallelic POMC, PCSK1 and LEPR deficiencies -- BOSTON, Nov. ...
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE® (setmelanotide) in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology
November 08, 2022 07:05 ET
|
Rhythm Pharmaceuticals, Inc.
-- Previously disclosed data demonstrated statistically significant and clinically meaningful reductions in weight and hunger in patients with Bardet-Biedl syndrome -- BOSTON, Nov. 08, 2022 (GLOBE...
Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update
November 08, 2022 07:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- U.S. launch of IMCIVREE® (setmelanotide) for Bardet-Biedl Syndrome progresses with strong demand with more than 120 prescriptions since FDA approval -- -- EC authorization for IMCIVREE expanded to...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
November 07, 2022 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces 11 Presentations at The Obesity Society’s Annual Meeting at ObesityWeek®
November 03, 2022 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- Analyses of Clinical Registry Investigating Bardet-Biedl Syndrome (CRIBBS) in children with BBS showed a significant positive correlation between degree of hyperphagia and body mass index (BMI) -- ...
Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity at ObesityWeek® and Plans to Initiate Phase 3 Trial in Early 2023
November 02, 2022 07:30 ET
|
Rhythm Pharmaceuticals, Inc.
-- Phase 3 clinical trial design reflects feedback obtained during recent discussions with FDA -- -- 89 percent (16 of 18) patients achieved primary endpoint with a BMI decrease greater than 5...
Rhythm Pharmaceuticals Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity by the U.S. FDA
November 01, 2022 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals to Present Full Data from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity at ObesityWeek® 2022
October 25, 2022 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- Rhythm to review data on webcast conference call on November 2, 2022 at 8:30 a.m. ET – -- Rhythm to report 3Q 2022 earnings on November 8, 2022 at 8:00 a.m. ET -- BOSTON, Oct. 25, 2022 (GLOBE...